Table of Content

1. Executive Summary
   1.1. Europe Platelet Rich Plasma Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 – 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Challenges
       2.2.5. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Europe Sectorial Outlook
       2.3.2. Europe GDP Growth Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
   3.1. Product Adoption Analysis
   3.2. Regulatory Landscape
   3.3. Value Chain Analysis
   3.4. Key Deals and Mergers
   3.5. PESTLE Analysis
   3.6. Porter’s Five Force Analysis
4. Price Trend Analysis, 2019 – 2031
   4.1. Key Highlights
   4.2. Key Factors Impacting Product Prices
   4.3. Pricing Analysis, By Product Type
   4.4. Regional Prices and Product Preferences
5. Europe Platelet Rich Plasma Market Outlook: Historical (2019 – 2023) and Forecast (2024 – 2031)
   5.1. Key Highlights
       5.1.1. Market Volume (Units) Projections
       5.1.2. Market Size (US$ Mn) and Y-o-Y Growth
       5.1.3. Absolute $ Opportunity
   5.2. Market Size (US$ Mn) Analysis and Forecast
       5.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
       5.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024–2031
   5.3. Europe Platelet Rich Plasma Market Outlook: Product Type
       5.3.1. Introduction / Key Findings
       5.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Product Type, 2019-2023
       5.3.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Product Type, 2024–2031
           5.3.3.1. Pure Platelet Rich Plasma (P-PRP)
           5.3.3.2. Leukocyte-rich Platelet Rich Plasma (L-PRP)
           5.3.3.3. Leukocyte-Platelet-Rich Fibrin (L-PRF)
           5.3.3.4. Pure Platelet Rich Fibrin (P-PRF)
           5.3.3.5. Others
   5.4. Market Attractiveness Analysis: Product Type
   5.5. Europe Platelet Rich Plasma Market Outlook: Origin
       5.5.1. Introduction / Key Findings
       5.5.2. Historical Market Size (US$ Mn) Analysis, By Origin, 2019-2023
       5.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Origin, 2024–2031
           5.5.3.1. Autologous
           5.5.3.2. Homologous
           5.5.3.3. Allogeneic
   5.6. Market Attractiveness Analysis: Origin
   5.7. Europe Platelet Rich Plasma Market Outlook: Application
       5.7.1. Introduction / Key Findings
       5.7.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
       5.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024–2031
           5.7.3.1. Orthopedic Surgery
           5.7.3.2. Cosmetic Surgery
           5.7.3.3. General Surgery
           5.7.3.4. Neurosurgery
           5.7.3.5. Others
   5.8. Market Attractiveness Analysis: Application
6. Europe Platelet Rich Plasma Market Outlook: Country
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Country, 2019-2023
   6.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Country, 2024–2031
       6.3.1. Germany
       6.3.2. France
       6.3.3. U.K.
       6.3.4. Italy
       6.3.5. Spain
       6.3.6. Russia
       6.3.7. Türkiye
       6.3.8. Rest of Europe
   6.4. Market Attractiveness Analysis: Country
7. Competition Landscape
   7.1. Market Share Analysis, 2023
   7.2. Market Structure
       7.2.1. Competition Intensity Mapping By Market
       7.2.2. Competition Dashboard
   7.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
       7.3.1. Arthrex, Inc.
           7.3.1.1. Overview
           7.3.1.2. Segments and Product Types
           7.3.1.3. Key Financials
           7.3.1.4. Market Developments
           7.3.1.5. Market Strategy
       7.3.2. Stryker Corporation
       7.3.3. Johnson and Johnson Ltd.
       7.3.4. Zimmer Biomet Holdings Inc.
       7.3.5. Terumo Corporation
       7.3.6. Glofinn Oy
       7.3.7. Medira Ltd.
       7.3.8. Regen Lab S.A.
8. Appendix
   8.1. Research Methodology
   8.2. Research Assumptions
   8.3. Acronyms and Abbreviations